

Disclosures

Personal Commercial (17)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AbbVie, Inc.	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Other</i>
AlwithCare	Stock	None (\$0)	<i>Other</i>
Amgen Inc.	Research/Research Grants ‡ OCEAN(a)	Significant (>= \$5,000)	<i>General Cardiology</i>
Arboretum Bioscience	Stock	Modest (< \$5,000)	<i>Other</i>
AstraZeneca Pharmaceuticals	Data Safety Monitoring Board	Modest (< \$5,000)	
Boehringer Ingelheim Pharmaceuticals, Inc	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Other</i>
Bristol-Myers Squibb Company	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Hanmi	Data Safety Monitoring Board	Modest (< \$5,000)	<i>General Cardiology</i>
Health [at] Scale	Ownership Interest/Partnership/Principal	Modest (< \$5,000)	<i>General Cardiology</i>
Lexeo	Data Safety Monitoring Board	Modest (< \$5,000)	<i>General Cardiology</i>
Merck & Co., Inc.	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Novo Nordisk Inc.	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
Pfizer Inc	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Verve Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Stable Ischemic Heart Disease</i>
<i>Spouse/Domestic Partner/Immediate Household Member</i>			
Vertex Pharmaceuticals	Salary	Significant (>= \$5,000)	<i>Other</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2018	Testosterone Replacement Therapy	Defendant		Significant (>= \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/10/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/10/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 7/10/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/22/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.